A Single-center, Investigator-blind, Subject Blind, Randomized, Placebo-controlled Study to Evaluate Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2019
Price : $35 *
At a glance
- Drugs UCB-0107 (Primary)
- Indications Alzheimer's disease; Progressive supranuclear palsy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors UCB Biopharma
- 13 Mar 2019 Status changed from active, no longer recruiting to completed.
- 29 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 14 Aug 2018 Status changed from not yet recruiting to recruiting.